Barclays’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Barclays’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,517	Closed	-$106K	–	5471
2023 Q4	$106K	Sell	10,517 -301,003	-97%	-$1.37M	﹤0.01%	4627
2023 Q3	$897K	Buy	311,520 +301,003	+2,862%	+$1.1M	﹤0.01%	2407
2023 Q2	$40.1K	Sell	10,517 -191,808	-95%	-$537K	﹤0.01%	3924
2023 Q1	$376K	Buy	202,325 +116,216	+135%	+$243K	﹤0.01%	3453
2022 Q4	$198K	Buy	86,109 +47,379	+122%	+$145K	﹤0.01%	3848
2022 Q3	$125K	Sell	38,730 -1,700	-4%	-$5.53K	﹤0.01%	3441
2022 Q2	$222K	Buy	+40,430	New	+$126K	﹤0.01%	3372

Barclays's GRCL Position: Q1 2024 in Review

Barclays sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 10,517 shares — an estimated $106K sold.

Barclays first reported a position in GRCL in Q2 2022 and held it in 7 quarters. The position peaked at $897K in Q3 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Barclays reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Barclays sold 10,517 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $106K.
Barclays first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q2 2022 and held it in 7 quarters.
Barclays's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $897K in Q3 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Barclays's 13F filing for Q1 2024, filed 15 May 2024.